mediaire transforms radiology with AI
Start-up securing a European €12 million investment to fuel global growth
While Generative AI is creating a buzz across industries and remains in the early stages of the hype cycle, AI in radiology is no longer just a vision for the future. mediaire’s proven AI value is already happening in over 350 hospitals and clinics across Europe, where the German radiology innovator’s AI portfolio is transforming how radiologists work. With this success, mediaire has secured a €12 million European-led financing round, headed by lead investor LBO France with participation from IBB Ventures and the Swiss family office Wille Finance. It highlights the importance of demonstrating that AI technology truly works in clinical practice. The oversubscribed financing round included continued support from existing investors HTGF, LIFTT, and Gateway Ventures.
By seamlessly integrating AI into daily diagnostics, mediaire is lifting the burden of routine analysis off the shoulders of radiologists, reducing medical workload, and improving patient outcomes. Thanks to the recent investment mediaire is set to expand its AI portfolio beyond brain, prostate, and knee diagnostics in magnetic resonance imaging (MRI). This next wave of innovation will tackle even more AI solutions, bringing AI-driven accuracy and efficiency to doctors globally. The funding marks a new phase in the company’s growth.
“Our AI solutions are not a futuristic dream. We have already created a reality that is helping doctors make better decisions and giving patients faster answers,” says Dr. Andreas Lemke, CEO, and co-founder of mediaire. “We are seeing the impact on thousands of radiologists every day in hundreds of hospitals and radiology practices across Europe that are utilizing our AI solutions. With this investment, we will be able to scale these benefits to even more healthcare providers.”
“We believe in the power of technology to improve lives,” said Matthes Seeling, LBO France’s Investment Director. “mediaire’s focus aligns perfectly with our firm belief in the transformative power of healthcare technology to the benefit of all professionals and patients. The dedicated team meets a crucial need in the healthcare sector considering the increasing global demand for fast, accurate and affordable diagnostics. With this investment, we will actively sustain mediaire’s growth to achieve its ambitious objectives and consolidate its position as a leader in radiology AI in Europe.”
Integral to mediaire’s success story are partnerships with renowned university hospitals and industry leaders such as Bayer/Calantic, Sectra, deepc, as well as radiology chains like Med360, Evidia, Starvision, and RIMED/UNILABS.
Dr. Angelika Vlachou, Partner at HTGF, said: “We at HTGF have been very pleased with mediaire’s development over the past years, and believe the team has demonstrated the value it can add to its customers, the radiologists. The field of AI-based tools is advancing rapidly, and to be successful, companies need to demonstrate true product innovation that is precisely tailored to customer needs. We are excited to continue to support mediaire’s development.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
